Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on AUPH stock, giving a Buy rating on August 2.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Schwartz has given his Buy rating due to a combination of factors including Aurinia Pharmaceuticals’ strong financial performance and promising pipeline developments. The company reported impressive net product sales of $66.6 million for Lupkynis in the second quarter of 2025, surpassing both the firm’s and consensus estimates. This robust performance led to an upward revision of the full-year sales guidance, indicating confidence in continued growth.
Additionally, Aurinia is making significant progress in its pipeline, particularly with the planned clinical studies of aritinercept in autoimmune diseases. The positive first-in-human data for aritinercept suggests potential for once-monthly dosing, aligning with industry standards. The company’s healthy cash position and strategic share repurchase plan further reinforce its financial stability and shareholder value, supporting Schwartz’s optimistic outlook.
In another report released on August 2, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $12.00 price target.